Thursday, May 09, 2019 7:34:41 AM
“Our sales force is now comprised of 10 seasoned professionals, each with a proven track record of introducing disruptive cardiovascular technologies to the marketplace,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. “Our recurring technology revenue stream reflects a strong trajectory of quarter over quarter growth, and we continue to execute well on our strategic objectives, including driving the commercialization of Bioflux. Our anchor customers are now recommending Bioflux to their colleagues, allowing for our expansion into new and high-growth markets.”
Biotricity will continue to facilitate the development of future medical devices that are easy to utilize in either the physician’s office or the patient’s home, and in acute-care settings. These medical-grade devices are comfortable, small, and can offer precise remote data collection and more responsive care. In the coming year, the company will continue to evolve and adapt its technology for a wide range of medical applications.
“In recent months we have expanded our market penetration from 7 to 11 states, leaving us plenty of room for growth,” said Mr. Casey Shattuck, Global VP of Sales. “The growing connected-health market continues to fuel the demand for real-time, remote patient monitoring (RPM) devices, and offers our company tremendous opportunities to grow. Our focus now is to direct that growth into avenues where we can combine the greatest revenue opportunities with the greatest human capital. We have cutting-edge technology, a team of experts in place, and the increasing bandwidth to expand our geographic reach.”
To learn more, visit www.biotricity.com or follow on
https://www.biotricity.com/biotricity-provides-fiscal-fourth-quarter-update-sales-force-expansion-to-fuel-growth/
All posts are speculative and my opinion only. NOT investment advice.
Recent BTCY News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 10:02:19 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/14/2024 10:18:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 10:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 09:55:34 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 10/18/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 12:15:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/19/2023 08:57:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/17/2023 12:38:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:26:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:15:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:14:24 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 07/17/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 08:05:35 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 09:29:39 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM